Aduro Biotech Inc. (NASDAQ:ADRO) traded down 4.9% during mid-day trading on Tuesday . The stock traded as low as $12.71 and last traded at $12.71, with a volume of 88,655 shares. The stock had previously closed at $13.37.

Several equities research analysts recently issued reports on the stock. FBR & Co reaffirmed a “buy” rating on shares of Aduro Biotech in a research note on Friday, April 29th. Canaccord Genuity reaffirmed a “buy” rating on shares of Aduro Biotech in a research note on Tuesday, May 3rd. Zacks Investment Research downgraded shares of Aduro Biotech from a “hold” rating to a “sell” rating in a research note on Monday. Leerink Swann reaffirmed a “buy” rating and set a $48.00 price target on shares of Aduro Biotech in a research note on Thursday, May 5th. Finally, Roth Capital reaffirmed a “buy” rating and set a $22.00 price target (down previously from $46.00) on shares of Aduro Biotech in a research note on Monday, May 16th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $24.17.

The company’s market capitalization is $882.59 million. The firm has a 50 day moving average of $11.94 and a 200-day moving average of $13.98.

Aduro Biotech (NASDAQ:ADRO) last released its quarterly earnings data on Monday, May 2nd. The company reported ($0.45) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by $0.20. On average, analysts forecast that Aduro Biotech Inc. will post ($1.24) earnings per share for the current fiscal year.

In other Aduro Biotech news, insider Thomas W. Dubensky sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 5th. The shares were sold at an average price of $11.61, for a total value of $290,250.00. Following the completion of the sale, the insider now directly owns 13,939 shares of the company’s stock, valued at $161,831.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

An institutional investor recently raised its position in Aduro Biotech stock. Jennison Associates LLC raised its stake in Aduro Biotech Inc. (NASDAQ:ADRO) by 9.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 855,338 shares of the company’s stock after buying an additional 74,073 shares during the period. Jennison Associates LLC owned about 1.35% of Aduro Biotech worth $24,069,000 as of its most recent SEC filing.

Aduro Biotech, Inc is a clinical-stage immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases. Its technologies are based on live, attenuated, double-deleted Listeria mononcytogenes (LADD) and cyclic dinucleotides (CDNs).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.